For millions of people worldwide, the nightly ritual of trying to fall asleep is less a transition into rest and more a battle against a racing mind, persistent wakefulness, or the frustration of fragmented sleep. Insomnia is a pervasive condition that extends far beyond the exhaustion of a poor night’s rest; it can severely disrupt daily functioning, erode emotional resilience, and heighten the risk of developing secondary mental health struggles, including chronic anxiety and clinical depression.
In the search for relief, patients and clinicians have increasingly turned their attention toward medical cannabis. As interest in the therapeutic potential of the plant grows, so too does the prevalence of medical cannabis products—ranging from oils and sprays to precise oral tablets—formulated with specific ratios of cannabinoids like THC and CBD. Unlike the recreational market, these regulated products are intended to offer a controlled medical intervention. However, a major new scientific review has sounded a note of caution, suggesting that despite the widespread enthusiasm, the current body of evidence is far too thin to definitively support the use of cannabis as a standard treatment for sleep disorders.
A Scrutiny of Existing Evidence
The comprehensive review, conducted by researchers from The Cochrane Associate Centre at the Universidad Hospital Italiano de Buenos Aires and the University of Manitoba, sought to cut through the noise of anecdotal success stories and marketing claims. By examining nine distinct clinical studies involving a total of 537 adults—ranging in age from 18 to 76—the researchers looked for rigorous, data-driven answers to a simple question: Does medical cannabis actually help people sleep better?
The participants in these trials were primarily individuals diagnosed with primary insomnia, meaning their struggle with sleep was not secondary to other diagnosed medical conditions. The methodology of the trials was varied, though most leaned on the gold standard of clinical research: eight of the nine trials compared a regulated medical cannabis product against a placebo, while one trial compared cannabis against amitriptyline, a tricyclic antidepressant often prescribed off-label for its sedative properties.
When the researchers synthesized the data from the placebo-controlled trials, the results were sobering. Across the board, medical cannabis failed to show any clinically meaningful improvement in key metrics, such as sleep quality, patient satisfaction with their rest, total sleep duration, or the ability to function effectively during waking hours. While patients often report feeling "better" on an anecdotal basis, the data simply did not bear out these claims when subjected to controlled scrutiny.
The Trade-Off: Side Effects and Uncertain Outcomes
Beyond the lack of proven efficacy, the review highlighted concerns regarding the safety profile of medical cannabis for sleep. Participants who were administered cannabis products were notably more likely to report mild, yet disruptive, side effects compared to those in the placebo groups. The most frequently cited issues included persistent dry mouth and feelings of dizziness—physical discomforts that, while perhaps not dangerous in a clinical sense, can negatively impact a patient’s overall experience and adherence to treatment.
The researchers acknowledged, however, that these findings regarding side effects were drawn from a relatively small pool of data, which limits the degree of confidence one can have in the results. Similarly, while there was a faint signal in the data suggesting that medical cannabis might contribute to an improvement in a patient’s overall quality of life, the evidence was described as "highly uncertain." When the researchers combined the disparate findings, the results were so broad that they ranged from a slight decline in quality of life to a modest improvement, making it impossible to draw a clear conclusion.
"The main message is that the research currently available is not sufficient to reliably answer whether medical cannabis helps people with insomnia," explains Dr. Lucia Varela, lead author of the study from the University of Manitoba. "This does not mean that medical cannabis is ineffective. It means that, based on the evidence we have, we cannot draw reliable conclusions about its effectiveness for insomnia in the general population."
Why the Scientific Community Remains Skeptical
The hesitation among the scientific community is not merely a result of the negative findings; it is largely a critique of the quality of the studies themselves. The reviewers assigned a "low" or "very low" confidence rating to the available body of evidence. Several systemic issues plagued the trials, including small participant cohorts that lacked statistical power, conflicting outcomes that made consensus difficult, and the potential for bias in how the individual trials were structured and reported.
Another significant hurdle is the lack of standardization. Because different trials utilized different cannabis formulations, delivery methods, and dosing schedules, it is nearly impossible for researchers to conduct an "apples-to-apples" comparison. Without a standardized product, it is difficult to determine whether a specific formulation might hold promise while others do not. Furthermore, the studies were remarkably short in duration. The longest trial followed participants for a mere 12 weeks. In the context of a chronic, long-term condition like insomnia, a 12-week window leaves critical questions unanswered: Does the efficacy of the treatment wane over time? Are there long-term health consequences to sustained, nightly use of these cannabinoids?
The Need for Rigorous Future Research
The demographic limitations of the existing studies also suggest that current findings may not be broadly applicable. The participant pool was heavily skewed, with women accounting for nearly 73% of the total subjects, and the majority of individuals being on the younger end of the adult age spectrum. This lack of diversity raises questions about how these treatments might interact with the physiology of men, older adults, or individuals managing complex, comorbid health conditions.
The researchers emphasize that this review should not be viewed as an absolute rejection of cannabis as a medicinal tool. Rather, it serves as a wake-up call for the medical and research communities to prioritize larger, more rigorous, and more diverse clinical trials. The rapid growth of the medical cannabis industry has, in many ways, outpaced the science, creating a gap where patients are seeking treatment for a very real and debilitating condition, but where clinicians lack the high-quality evidence required to provide sound medical guidance.
Dr. Luis Garegnani, the senior author of the study from the Universidad Hospital Italiano de Buenos Aires, stresses that the current uncertainty is the most important takeaway for both practitioners and patients. "The evidence is too weak and uncertain to draw firm conclusions about the use of medical cannabis for insomnia," he notes. "Rather than viewing the findings as either an endorsement or a rejection of medical cannabis, clinicians and patients should recognize the uncertainty and consider individual circumstances while better evidence is generated."
For now, the message to those suffering from sleeplessness is one of caution. While the allure of a new treatment option is understandable, the current scientific landscape suggests that the promise of medical cannabis for insomnia remains, for the moment, unproven. Until more robust data becomes available, experts advise that patients continue to rely on established, evidence-based treatments such as cognitive behavioral therapy for insomnia—which helps address the underlying thoughts and habits that keep people awake—and other medications whose efficacy profiles are more clearly understood. The path to a better night’s sleep, it seems, still requires more research before cannabis can be considered a reliable destination.

